Markets

Trump Reverses Course to Fast-Track Psychedelic Drugs for Mental Healthcare

The president is pushing to accelerate research into psychedelics as mental health treatments, creating new investment opportunities alongside regulatory risks.

Trump Reverses Course to Fast-Track Psychedelic Drugs for Mental Healthcare
Read the full reporting at CNBC Markets.

Originally reported by CNBC Markets.

psychedelic drugs mental health pharmaceutical research Trump administration FDA approval biotech investment